Effect of Porins and blaKPC Expression on Activity of Imipenem with Relebactam in Klebsiella pneumoniae: Can Antibiotic Combinations Overcome Resistance?

被引:43
作者
Balabanian, Gregory
Rose, Michael
Manning, Nyla
Landman, David
Quale, John
机构
[1] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA
[2] Suny Downstate Med Ctr, Div Infect Dis, Brooklyn, NY 11203 USA
关键词
Klebsiella pneumoniae; relebactam; carbapenemase; CEFTAZIDIME-AVIBACTAM RESISTANCE; ENTEROBACTERIACEAE; SUSCEPTIBILITY; PATHOGENS;
D O I
10.1089/mdr.2018.0065
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Imipenem with relebactam is a novel beta-lactam-beta-lactamase inhibitor that has activity against most KPC-producing Enterobacteriaceae. Using 10 isolates of KPC-possessing Klebsiella pneumoniae, we assessed the relationship between imipenem-relebactam minimum inhibitory concentrations (MICs) and mechanisms known to contribute to antimicrobial resistance. The effect of adding a second agent was assessed by time-kill experiments. Mutations affecting the genes encoding porins ompK35 and ompK36 and identification of beta-lactamases were assessed by PCR. Expression of bla(KPC) and acrB was assessed by real-time reverse-transcriptase (RT)-PCR, and production of OmpK36 by SDS-PAGE. Time-kill studies were performed using combinations of imipenem-relebactam with polymyxin B, amikacin, or tigecycline. Seven isolates having a disruption in a single porin, or in neither porin, remained susceptible to imipenem-relebactam. The addition of a second agent did not improve the activity of imipenem-relebactam for these isolates, although the addition of tigecycline was antagonistic for three isolates. Three isolates had major disruptions in both ompK35 and ompK36 that correlated with reduced activity of imipenem-relebactam (MICs 2/4, 8/4, and 512/4 mu g/mL). Two of these isolates also had overexpression of bla(KPC), including the isolate with the highest MIC. These isolates were also resistant to polymyxin B and amikacin. The addition of amikacin provided both synergistic and bactericidal activity for the two more resistant isolates. The activity of imipenem-relebactam against K. pneumoniae is affected by major disruptions of both ompK35 and ompK36 and by expression of the KPC gene. Combining imipenem-relebactam with an aminoglycoside may be a promising approach for isolates with reduced susceptibility to imipenem-relebactam.
引用
收藏
页码:877 / 881
页数:5
相关论文
共 14 条
[1]   Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates [J].
Diancourt, L ;
Passet, V ;
Verhoef, J ;
Grimont, PAD ;
Brisse, S .
JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (08) :4178-4182
[2]   Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae [J].
Haidar, Ghady ;
Clancy, Cornelius J. ;
Chen, Liang ;
Samanta, Palash ;
Shields, Ryan K. ;
Kreiswirth, Barry N. ;
Nguyen, M. Hong .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (09)
[3]   First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate [J].
Humphries, Romney M. ;
Yang, Shangxin ;
Hemarajata, Peera ;
Ward, Kevin W. ;
Hindler, Janet A. ;
Miller, Shelley A. ;
Gregson, Aric .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (10) :6605-6607
[4]  
Jacob JT, 2013, MMWR-MORBID MORTAL W, V62, P165
[5]   Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam [J].
Kazmierczak, Krystyna M. ;
Biedenbach, Douglas J. ;
Hackel, Meredith ;
Rabine, Sharon ;
de Jonge, Boudewijn L. M. ;
Bouchillon, Samuel K. ;
Sahm, Daniel F. ;
Bradford, Patricia A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (08) :4490-4500
[6]   NOVEL ANTIBIOTIC REGIMENS AGAINST ENTEROCOCCUS-FAECIUM RESISTANT TO AMPICILLIN, VANCOMYCIN, AND GENTAMICIN [J].
LANDMAN, D ;
MOBARAKAI, NK ;
QUALE, JM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (09) :1904-1908
[7]   Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration [J].
Landman, David ;
Babu, Elizabeth ;
Shah, Neha ;
Kelly, Paul ;
Olawole, Olafisoye ;
Baecker, Martin ;
Bratu, Simona ;
Quale, John .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (06) :1427-1431
[8]   Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae [J].
Landman, David ;
Bratu, Simona ;
Quale, John .
JOURNAL OF MEDICAL MICROBIOLOGY, 2009, 58 (10) :1303-1308
[9]   Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City [J].
Lapuebla, Amabel ;
Abdallah, Marie ;
Olafisoye, Olawole ;
Cortes, Christopher ;
Urban, Carl ;
Quale, John ;
Landman, David .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) :4856-4860
[10]   Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City [J].
Lapuebla, Amabel ;
Abdallah, Marie ;
Olafisoye, Olawole ;
Cortes, Christopher ;
Urban, Carl ;
Landman, David ;
Quale, John .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) :5029-5031